Want to see DNTH full AI Analyst Report?
Top Page
Dianthus Therapeutics
(NASDAQ:DNTH)
Select Model
Select Model
Rating:55Neutral
Price Target:
$107.00
▲(3.01% Upside)
Action:Reiterated
Date:06/12/26
Overall score is held back most by ongoing losses and cash burn, plus weak near-term technical momentum. These are partly offset by a strong, low-leverage balance sheet and positive corporate developments (encouraging Phase 3 interim data and extended cash runway).
Positive Factors
Balance sheet strength
Extremely low leverage and sharply higher equity/assets give Dianthus durable financing flexibility to fund multi-year clinical programs. A strong balance sheet reduces near-term refinancing risk, supports sustained R&D investment and preserves optionality to pursue partnerships or M&A through 2026–2030.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow means the company must rely on financing to sustain operations absent a commercial product. Over the medium term this necessitates capital markets access, restricts discretionary spending and raises execution risk if clinical outcomes slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Extremely low leverage and sharply higher equity/assets give Dianthus durable financing flexibility to fund multi-year clinical programs. A strong balance sheet reduces near-term refinancing risk, supports sustained R&D investment and preserves optionality to pursue partnerships or M&A through 2026–2030.
Read all positive factors
Dianthus Therapeutics (DNTH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.71B
Dividend YieldN/A
Average Volume (3M)1.23M
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue Growth-79.52%
EPS Growth-43.40%
CountryUS
Employees92
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding54,666,233
10 Day Avg. Volume895,608
30 Day Avg. Volume1,227,272
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.16
Price to Sales (P/S)764.98
P/FCF Ratio-12.05
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue2.09K
Enterprise Value/Gross Profit2.22K
Enterprise Value/Ebitda-257.10
Forecast
1Y Price Target
$135.29Price Target Upside30.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.75
Revenue Forecast (FY)$1.19M
Dianthus Therapeutics Business Overview & Revenue Model
Company Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with exten...
How the Company Makes Money
null...
Dianthus Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
78
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.34M | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M |
| Gross Profit | 1.26M | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M |
| EBITDA | -10.86M | -161.91M | -84.56M | -43.20M | -28.33M | -11.09M |
| Net Income | -11.32M | -162.34M | -84.97M | -43.55M | -28.48M | -13.11M |
Balance Sheet | ||||||
| Total Assets | 1.25B | 530.92M | 374.01M | 179.41M | 83.11M | 189.93M |
| Cash, Cash Equivalents and Short-Term Investments | 1.11B | 404.30M | 275.24M | 173.72M | 75.49M | 176.93M |
| Total Debt | 1.36M | 1.39M | 1.49M | 585.00K | 788.00K | 0.00 |
| Total Liabilities | 45.57M | 37.52M | 21.53M | 10.54M | 9.45M | 17.26M |
| Stockholders Equity | 1.20B | 493.40M | 352.48M | 168.87M | 73.66M | 172.67M |
Cash Flow | ||||||
| Free Cash Flow | -130.49M | -129.27M | -78.28M | -36.97M | -29.21M | -60.80M |
| Operating Cash Flow | -130.29M | -129.06M | -78.18M | -36.86M | -29.07M | -59.53M |
| Investing Cash Flow | -271.60M | -122.83M | -286.81M | 20.25M | -59.82M | 43.43M |
| Financing Cash Flow | 1.02B | 280.13M | 255.62M | 133.57M | 96.68M | 89.60M |
Dianthus Therapeutics Technical Analysis
Positive
103.87
Price Trends
91.30
Positive
88.04
Positive
65.54
Positive
Market Momentum
4.13
Negative
58.90
Neutral
75.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNTH, the sentiment is Positive. The current price of 103.87 is above the 20-day moving average (MA) of 99.59, above the 50-day MA of 91.30, and above the 200-day MA of 65.54, indicating a bullish trend. The MACD of 4.13 indicates Negative momentum. The RSI at 58.90 is Neutral, neither overbought nor oversold. The STOCH value of 75.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DNTH.
Dianthus Therapeutics Risk Analysis
Dianthus Therapeutics disclosed 72 risk factors in its most recent earnings report. Dianthus Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dianthus Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $4.48B | -24.31 | -32.55% | ― | ― | -7.28% | |
58 Neutral | $2.17B | -13.21 | -55.68% | ― | ― | 51.42% | |
55 Neutral | $5.71B | -923.73 | -1.78% | ― | -79.52% | -43.40% | |
52 Neutral | $2.18B | -2.43 | -866.46% | ― | ― | 39.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $949.53M | -8.15 | -11.85% | ― | 47.10% | -35.51% | |
46 Neutral | $1.25B | -21.62 | -38.11% | ― | 18.24% | -5.21% |
* Healthcare Sector Average
DNTH
Dianthus Therapeutics
101.61
80.81
388.51%
ARDX
Ardelyx
5.00
0.66
15.21%
EWTX
Edgewise Therapeutics
40.35
26.12
183.56%
JANX
Janux Therapeutics Inc
15.00
-9.23
-38.09%
AMLX
Amylyx Pharmaceuticals Inc
19.55
11.58
145.29%
BHVN
Biohaven Ltd.
13.77
-1.83
-11.73%
Dianthus Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Dianthus Highlights Positive CAPTIVATE Phase 3 Interim Results
Positive
Jun 12, 2026
On June 11, 2026, Dianthus Therapeutics reported interim responder analysis data from the first 40 patients completing Part A of its Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy, showing a 75% respon...
Executive/Board ChangesShareholder Meetings
Dianthus Therapeutics Stockholders Reaffirm Board and Governance Structure
Positive
May 22, 2026
On May 21, 2026, Dianthus Therapeutics held its Annual Meeting of Stockholders, where investors elected Sujay Kango, Anne McGeorge and Jonathan Violin, Ph.D. as Class II directors to serve until the 2029 annual meeting, reaffirming the companyR...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.